|Description||AG 99, an EGF receptor tyrosine kinase inhibitor, has been found to show activities in diagnosis, prevention and treatment of cancer.|
|Purity||≥99% by HPLC|
HKI 357 is a potent and irreversible dual inhibitor of ErbB2 (HER2) and EGFR (IC50 = 33 and 34 nM, respectively). It inhibits EGFR autophosphorylation and proli...
Tyrphostin AG-528, also known as Tyrphostin B66, is an inhibitor of EGFR and ErbB2 with IC50s of 4.9 and 2.1 μM, respectively.
Trastuzumab is a monoclonal antibody drug for the treatment of breast cancer which is HER2 receptor positive. It acts via binding to HER2 receptor to suppress c...
BIBU 1361 dihydrochloride
BIBU 1361 dihydrochloride is an inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase (IC50 = 3 nM) with ~ 100-fold lower potency than ErbB2 (IC5...
RG14620 is a non-phenolic tyrphostin-class epidermal growth factor receptor (EGFR) inhibitor (IC50= 3 μM for HER 14 colony formation, and IC50= 1 pM for HER 14 ...
Mubritinib, also known as TAK-165, is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer. It completed phase I clinic...
AZD3759 is a n orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, AZD3...
WZ-3146 is an irreversiblely inhibitor against EGFR T790M with potential anticancer activity.